{"id":73614,"date":"2026-06-30T17:52:09","date_gmt":"2026-06-30T17:52:09","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/73614\/"},"modified":"2026-06-30T17:52:09","modified_gmt":"2026-06-30T17:52:09","slug":"barclays-assigns-overweight-rating-to-sab-biotherapeutics-inc-sabs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/73614\/","title":{"rendered":"Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)"},"content":{"rendered":"\n

SAB Biotherapeutics Inc. (NASDAQ:SABS<\/a>) is one of the 10 best stocks under $10 offering more than 50% upside<\/a>. <\/p>\n

On June 24, Eliana Merle from Barclays initiated coverage of SAB Biotherapeutics Inc. (NASDAQ:SABS) with a target price of $13, and assigned an Overweight rating to the stock. As per Merle’s projections, the stock currently offers a highly lucrative upside potential of more than 235%. <\/p>\n

<\/a> <\/p>\n

Copyright: kadmy \/ 123RF Stock Photo <\/p>\n

Image: Depositphotos <\/p>\n

According to Merle, SAB-142 has a substantial opportunity as a potential disease-altering treatment in the type 1 diabetes marketplace. The analyst believes that the Phase 2b data, which is anticipated in the latter half of 2027, will be the primary driver for the stock. <\/p>\n

Following the recent approval of Tzield, she views the regulatory process for SAB-142 as de-risked. Merle noted that the anticipated $4 billion potential for SAB-142, as a type 1 diabetes therapy, is not fully reflected in the company’s current market capitalization of $300 million. <\/p>\n

Back on May 22, Citi also initiated its coverage of the stock with a target price of $11, yielding an upside potential in excess of 184% at the prevailing level. The firm assigned a Buy rating to the stock, based on its view that the company is redefining the broader landscape for type 1 diabetes cure. The firm also acknowledged SAB’s efforts toward immune modulation based on a “clinically validated” framework. <\/p>\n

SAB Biotherapeutics Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. <\/p>\n

While we acknowledge the potential of SABS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0<\/a>best short-term AI stock<\/a>. <\/p>\n

READ NEXT:\u00a033 Stocks That Should Double in 3 Years<\/a> and 15 Stocks That Will Make You Rich in 10 Years<\/a>. <\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 offering more than 50% upside.…\n","protected":false},"author":2,"featured_media":73615,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[21264],"tags":[3343,33522,33521,10689,28998],"class_list":["post-73614","post","type-post","status-publish","format-standard","has-post-thumbnail","category-barclays","tag-barclays","tag-biotherapeutics","tag-eliana-merle","tag-potential","tag-type-1-diabetes"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116840336122945100","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/73614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=73614"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/73614\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/73615"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=73614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=73614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=73614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}